Cargando…

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

BACKGROUND: Neoadjuvant chemotherapy (NAC) with taxanes followed by fluorouracil, epirubicin, and cyclophosphamide (FEC), and concurrent trastuzumab is a potent regimen for HER2 over-expressing breast cancer. A high pathological complete response (pCR) rate has been achieved using this regimen; howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurozumi, Sasagu, Inoue, Kenichi, Takei, Hiroyuki, Matsumoto, Hiroshi, Kurosumi, Masafumi, Horiguchi, Jun, Takeyoshi, Izumi, Oyama, Tetsunari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562359/ https://www.ncbi.nlm.nih.gov/pubmed/26345461 http://dx.doi.org/10.1186/s12885-015-1641-y

Ejemplares similares

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70‐interacting protein in postmenopausal breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2018)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer
por: Yanai, Keiko, et al.
Publicado: (2020)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies
por: Zhou, Chen, et al.
Publicado: (2022)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study
por: Russo, Francesco, et al.
Publicado: (2013)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

Association of +331G/A PgR Polymorphism with Susceptibility to Female Reproductive Cancer: Evidence from a Meta-Analysis
por: Chaudhary, Sanjib, et al.
Publicado: (2013)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study
por: Paleari, Laura, et al.
Publicado: (2020)

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2022)

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
por: Holmes, Frankie Ann, et al.
Publicado: (2018)

Fluorouracil Catabolism in the Combination Treatment of Cyclophosphamide, Methotrexate and Fluorouracil
por: De Bruijn, Ernst A., et al.
Publicado: (1992)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy
por: Nakazawa, Yuko, et al.
Publicado: (2020)

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)
por: Riccardi, A, et al.
Publicado: (2001)

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
por: Wu, Wei, et al.
Publicado: (2021)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
por: Topham, C., et al.
Publicado: (1991)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Transient Effectiveness of an Oral 5-Fluorouracil Derivative, S-1, for Epirubicin, Cyclophosphamide and Paclitaxel Refractory Skin Metastases from Possible Occult Breast Cancer in a Male
por: Hirao, Ayaka, et al.
Publicado: (2011)

Immunohistochemical Expression of p27(Kip1), p57(Kip2), Cyclin D1, Nestin, and Ki-67 in Ependymoma
por: Iqneibi, Shahad, et al.
Publicado: (2022)

Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane
por: Aoyama, Nobutaka, et al.
Publicado: (2017)

Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study
por: Zhang, Mengmeng, et al.
Publicado: (2020)

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer
por: Dobrescu, Andrei, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_apsjq8f34sl8te7pdmpescqjb0